An observational study in Acute Coronary Syndromes, Heart Failure and Pulmonary Embolism, Deep Vein Thrombosis, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Acute Coronary Syndrome by Assistance Publique - Hôpitaux de Paris — 5 open to participants now, 5 under way, 1 of them phase 3. Acute Coronary Syndrome · Assistance Publique - Hôpitaux de Paris.
Among the 19 studies in Acute Coronary Syndrome by Assistance Publique - Hôpitaux de Paris, this one is the only one that started in 2026, is one of 8 observational ones, and was the 19th registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.
Browse Acute Coronary Syndrome studies →5 of the 19 studies in Acute Coronary Syndrome by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 15+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25,000 is above the median of 500 across 590 observational studies indexed under Acute Coronary Syndrome.
Median enrollment 380 across the 11 interventional studies, 335 across the 8 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
2 of the studies in Acute Coronary Syndrome by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05577988Phase 3Assistance Publique - Hôpitaux de ParisAssessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome | 2027-06 |
| NCT07675434Assistance Publique - Hôpitaux de ParisProspective Cohort of Acute Cardiology Referrals in an Ambulatory Day-Hospital Setting | 2027-02-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies in Acute Coronary Syndrome by Assistance Publique - Hôpitaux de Paris, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Suspected acute or subacute cardiovascular diseases-including chest pain, dyspnea, and palpitations-are among the most common reasons for unscheduled emergency department visits and pre-hospital referrals. Despite this high clinical burden, the diagnostic yield is often limited, with a frequent mismatch between initial clinical suspicion and final diagnosis, contributing to substantial healthcare utilization and hospitalization rates. Current evidence is largely focused on specific conditions such as acute coronary syndromes, heart failure, arrhythmias, or pulmonary embolism, and rarely integrates the full spectrum of clinical, biological, and imaging data obtained during initial evaluation.
To address this gap, we will establish a prospective cohort of all consecutive patients referred to the ambulatory day-hospital cardiology unit at Lariboisière University Hospital. This unit acts as a specialized downstream referral structure within the emergency care pathway, receiving patients after triage by emergency physicians, pre-hospital regulation services (SAMU), mobile intensive care units (SMUR), or emergency departments. Although it does not capture all suspected cardiovascular emergencies, it represents a selected real-world population deemed to require specialized acute cardiology assessment.
The primary objective is to assess the frequency of cardiac conditions diagnosed in this cohort. Secondary objectives include characterization of patient profiles and diagnostic pathways; evaluation of the diagnostic and prognostic performance of clinical, biological, imaging, and multimodal parameters using final Heart Team diagnosis as reference; analysis of prior health history and healthcare utilization; and assessment of the medico-economic burden of suspected acute cardiovascular disease. The study will further support the development of a dedicated biobank and the validation of next-generation biomarkers, including AI-driven and voice-based markers, as well as decision-support algorithms for binary classification of cardiac involvement. Through integration of multimodal data and linkage with national health records, this approach aims to improve diagnostic accuracy, risk stratification, and understanding of the healthcare impact of acute cardiovascular presentations in a real-world setting.
Consecutive patients referred to ambulatory day-hospital unit for suspicion of acute or sub-acute cardiovascular disease at the Cardiology Department of Lariboisière University Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- The study will include all consecutive patients referred to ambulatory day-hospital unit for suspicion of acute or sub-acute cardiovascular disease at the Cardiology Department of Lariboisière University Hospital.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Proportion of patients with confirmed cardiovascular diagnosis among consecutive patients consulting for suspicion of acute or sub-acute cardiovascular disease at the ambulatory day-hospital unit.
Time frame: From enrollement to six months of follow-up.
Proportion referred to cardiac computed tomography (CCT)
Time frame: From enrollement to six months of follow-up.
Proportion referred to cardiovascular magnetic resonance (CMR)
Time frame: From enrollement to six months of follow-up.
Proportion referred to stress tests.
Time frame: From enrollement to six months of follow-up.
Proportion referred to Holter monitoring or implantable loop recorders
Time frame: From enrollement to six months of follow-up.
Proportion with introduction of heart failure (HF) therapy
Time frame: From enrollement to six months of follow-up.
Proportion with introduction of anti-platelet therapy
Time frame: From enrollement to six months of follow-up.
Proportion with introduction of anti-coagulant therapy
Time frame: From enrollement to six months of follow-up.
Proportion referred to percutaneous coronary intervention (PCI)
Time frame: From enrollement to six months of follow-up.
Proportion referred to cardiac surgery
Time frame: From enrollement to six months of follow-up.
Proportion referred to electrical cardioversion
Time frame: From enrollement to six months of follow-up.
Proportion referred to catheter ablation
Time frame: From enrollement to six months of follow-up.
Proportion referred to pacemaker implantation
Time frame: From enrollement to six months of follow-up.
Proportion referred to defibrillator implantation
Time frame: From enrollement to six months of follow-up.
Diagnostic performance of each initial parameter with: sensitivity, specificity, positive predictive value, negative predictive value, and area under the ROC curve.
Time frame: From enrollement to six months of follow-up.
Cost of care pathways initial and up to 2-5 years
Time frame: From enrollement to five years of follow-up.
Prognostic value of baseline features to predict medical events annually up to 10 years of follow-up
The occurrence of: 1. All-cause mortality 2. Cardiovascular mortality 3. Sudden cardiac death 4. Hospitalization for any cardiovascular reason and duration of hospitalization 5. Hospitalization for HF 6. Myocardial infarction (MI) 7. Stroke 8. Incident atrial fibrillation (AF) 9. Cardiac syncope 10. Incident ventricular arrhythmia 11. Cardiac surgery 12. Coronary revascularization including PCI and coronary artery bypass grafting (CABG) m. Valvular percutaneous intervention (TAVI, TMVI, mitral or tricuspid clips...) n. Electrophysiological studies (catheter ablation, pacemaker / defibrillator implantation...)
Time frame: From enrollement to ten years of follow-up.
Cost-effectiveness of the CESAR care pathway
Cost-effectiveness of the CESAR care pathway compared with a propensity score-matched control population extracted from the French national health claims database.
Time frame: From enrollement to five years of follow-up.
F1 score of the artificial intelligence model for detecting cardiac involvement
Time frame: From enrollement to six months of follow-up.
Prognostic value of voice-derived acoustic and speech parameters
The occurrence of: a. All-cause mortality b. Cardiovascular mortality c. Sudden cardiac death d. Hospitalization for any cardiovascular reason and duration of hospitalization
Time frame: At enrollement (D0).
Number of sick leave
Time frame: From enrollement to five years of follow-up.
Five-year event-free survival
Event-free survival in patients managed through the CESAR care pathway compared with a propensity score-matched control population extracted from the French national health claims database.
Time frame: From enrollement to five years of follow-up.
Area under the precision-recall curve (PR-AUC) of the artificial intelligence model for detecting cardiac involvement
Time frame: From enrollement to six months of follow-up.
Area under the receiver operating characteristic curve (ROC-AUC) of the artificial intelligence model for detecting cardiac involvement
Time frame: From enrollement to six months of follow-up.
Duration of sick leave
Cumulative duration of sick leave during follow-up in days.
Time frame: From enrollement to five years of follow-up.
No study locations are listed for this record.
Start is estimated for Aug 2026; primary completion for Feb 2027, 6 months later.
Of 243 non-industry observational studies under Acute Coronary Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 6 months is below that.
Counting every sponsor, half of 277 studies reached it within 35 months; a quarter within 18 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →